In part 3 of this Exclusive Interview, Keith Campbell shares his thoughts about upcoming developments in diabetes care with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.
Having been an instrumental change in the way pharmacists practice pharmacy, Professor Emeritus R. Keith Campbell, RPh, MBA, CDE, FASHP, FAPhA, FAADE, is the former Associate Dean and Distinguished Professor in Diabetes Care/Pharmacotherapy at the Washington State University College of Pharmacy in Pullman, Washington.
Transcript of this video segment:
Steve Freed: You’ve deal with a lot of drug company. What do you know of or what’s in the pipeline? You mentioned a few things that is probably going to be out very shortly, but looking into the future, diabetes has changed dramatically because of the new drugs and new technologies. It took us 50 years to go from one drug to two drugs. Now it happens every 6 weeks. What do you see in the future, from your history and looking into these things, because you have a huge interest in diabetes. What do you see coming down the pike?
Keith Campbell: I think we’re going to better studies and we’re going to market the studies better. One of the statistics it’s always kind of concern me is that in most medical schools, primary care physicians get 4 hours of lecture on diabetes. So, then they get out to practice and they get a patient with diabetes and they simplify the treatment. They really don’t like putting people on injectables, especially insulin because they can get hypoglycemic and have a wreck, or something like that. Whereas if we really understand how to take care of diabetes, we could avoid a lot of that. We’re going to see an explosion of apps for your smartphone. We’re going to see better, smarter pumps. We’re going to get smaller devices that can sense your glucose continuously that need less calibration under smaller and easier to insert and talk to your pumps and so on. That whole area, I think is going to explode in a big way. The types of medications we have, 12 to 13 different classes of drugs depending on you count them. The combination of those drugs, either in fix doses or add one to another, whatever, can really help most people with type 2 diabetes get under good control. I think as we get more and more studies, were going to see this fine-tuned and we’re going to see outcomes in terms of your average blood sugars. I started on Jardiance (Empagliflozin), an SGLT2 inhibitor…
Steve Freed: And that’s off label.
Keith Campbell: Yes, but I’ve always believed the physiology of, the pharmacology of how it works is that the big market for the company was to treat type 2 because that’s where most of the patients are, but I think they’re doing studies in type one. But since I’ve been on that I seldom have a blood sugar over 200. What’s interesting is I hardly ever get below 70 or 60, so it’s really reduce my hypos, which doesn’t necessarily make sense. So, I read a lot about it, I keep hydrated. If anything happens to me in terms of a trauma, infection or anything like that, ysou really watch your blood sugars closer to avoid any possible complications. I think you’re going to see more drugs being brought out that treat type 1 diabetes in addition to insulin and I think the SGLT2 are going to be good. Novo has some interesting research with an oral GLP-1 agonist (semaglutide). I’m pretty excited about that and the reason I am is that when it’s brought out orally and if It has the impact it looks like it might have, they’re going to just blow away the GLP-1 market in my opinion.